Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489464 | 0.93 | ALDH1A1 (0.50) | LMNAGAAALDH1A1TSHRMEN1 | |
| SCHEMBL489570 | 0.93 | LMNA (0.63) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL490274 | 0.88 | LMNA (0.55) | LMNAGAAALDH1A1TSHRPOLB | |
| SCHEMBL489753 | 0.85 | ADORA3 (0.47) | LMNAGAAALDH1A1TSHRMEN1 | |
| SCHEMBL489370 | 0.82 | LMNA (0.59) | LMNAGAAALDH1A1TSHRMEN1 | |
| SCHEMBL13436314 | 0.80 | CACNA1F (0.44) | LMNAGAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL10112948 | 0.78 | MEN1 (0.74) | LMNAGAAALDH1A1TSHRMEN1 | |
| SCHEMBL489865 | 0.77 | MTOR (0.50) | LMNAGAAALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL489592 | 0.77 | PPARA (0.52) | LMNAGAAALDH1A1TSHRMEN1 | |
| SCHEMBL6689694 | 0.76 | ALDH1A1 (0.51) | LMNAALDH1A1TSHRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | claimed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | claimed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | claimed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | claimed |
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | LMNA 3818/4885GAA 2735/4885ALDH1A1 1580/4885 |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | ORAI1, CACNA1B, CACNA1I | LMNA 4286/4885GAA 2582/4885ALDH1A1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.